R-ISS / R2-ISS staging
R-ISS is the myeloma staging system, combining blood markers with high-risk chromosome changes to predict outcome.
Revised International Staging System (2015): β2-microglobulin, albumin, LDH and high-risk FISH (del17p, t(4;14), t(14;16)). R2-ISS (2022) adds 1q gain/amplification and weights factors. Median OS is not reached for stage I and ~4-5 years for stage III in older cohorts; modern quadruplets shift all groups.
Pages like this
not linked directly; found by shared links- TermHigh-risk cytogenetics (myeloma)
Shares Multiple Myeloma Research Foundation (MMRF), Ubiquitin–proteasome system & protein homeostasis, Multiple myeloma.
- ProductMezigdomide
Shares Ubiquitin–proteasome system & protein homeostasis, Multiple myeloma.
- TermMRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)
Shares S. Vincent Rajkumar, Multiple Myeloma Research Foundation (MMRF), Multiple myeloma.
- ProductIberdomide
Shares Ubiquitin–proteasome system & protein homeostasis, Multiple myeloma.
- ProductIxazomib
Shares Ubiquitin–proteasome system & protein homeostasis, Multiple myeloma.
- ProductPomalidomide
Shares Ubiquitin–proteasome system & protein homeostasis, Multiple myeloma.
- TargetGPRC5D
Shares Multiple Myeloma Research Foundation (MMRF), Multiple myeloma.
- ProductCarfilzomib
Shares Ubiquitin–proteasome system & protein homeostasis, Multiple myeloma.